e.g. mhealth
Search Results (1 to 3 of 3 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Research Protocols
- 1 JMIR Serious Games
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Traditional methods for managing perioperative anxiety often rely on pharmacological interventions, with oral midazolam being a commonly used anxiolytic agent. Administered at a typical dosage of 0.25 to 0.5 mg/kg, midazolam is effective in reducing anxiety in children, inducing sedation and anxiolysis within 20 to 30 minutes [6,7]. Studies have shown that midazolam premedication can significantly improve cooperation during anesthesia induction and decrease postoperative behavioral disturbances [8,9].
JMIR Serious Games 2025;13:e67007
Download Citation: END BibTex RIS
All parameters used in the calculations are detailed for epinephrine (Table 1) and for norepinephrine, dopamine, and midazolam (Multimedia Appendix 2). Analyses were performed using Microsoft Excel 2016 (version 16.0.5254.1000).
J Med Internet Res 2024;26:e52077
Download Citation: END BibTex RIS
Overall, there is limited robust evidence to guide the use of dexmedetomidine or midazolam as end-of-life sedatives in the palliative care population.
Given the knowledge gap, the investigators proposed a randomized controlled trial, “Dexmedetomidine for the Reduction of End-of-life Agitation and for opti Mised Sedation” (DREAMS). This trial aimed to investigate the use of dexmedetomidine versus midazolam by CSCI in patients for sedation at the end of life.
JMIR Res Protoc 2024;13:e55129
Download Citation: END BibTex RIS